% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Burger:838853,
      author       = {Burger, MC and Ronellenfitsch, MW and Lorenz, NI and
                      Wagner, M. and Voss, M. and Capper, D. and Tzaridis, T. and
                      Herrlinger, U. and Steinbach, P. and Stoffels, Gabriele and
                      Langen, Karl-Josef and Brandts, C. and Senft, C. and Harter,
                      PN and Bähr, O.},
      title        = {{D}abrafenib in patients with recurrent, {BRAF} {V}600{E}
                      mutated malignant glioma and leptomeningeal disease},
      journal      = {Oncology reports},
      volume       = {38},
      number       = {6},
      issn         = {1021-335X},
      address      = {Athens},
      publisher    = {Spandidos Publ.},
      reportid     = {FZJ-2017-07363},
      pages        = {3291-3296},
      year         = {2017},
      abstract     = {BRAF V600E mutations occur frequently in malignant
                      melanoma, but are rare in most malignant glioma subtypes.
                      Besides, more benign brain tumors such as ganglioglioma,
                      dysembryoblastic neuroepithelial tumours and supratentorial
                      pilocytic astrocytomas, only pleomorphic xanthoastrocytomas
                      $(50–78\%)$ and epitheloid glioblastoma $(50\%)$ regularly
                      exhibit BRAF mutations. In the present study, we report on
                      three patients with recurrent malignant gliomas harbouring a
                      BRAF V600E mutation. All patients presented with markedly
                      disseminated leptomeningeal disease at recurrence and had
                      progressed after radiotherapy and alkylating chemotherapy.
                      Therefore, estimated life expectancy at recurrence was a few
                      weeks. All three patients received dabrafenib as a single
                      agent and all showed a complete or nearly complete response.
                      Treatment is ongoing and patients are stable for 27 months,
                      7 months and 3 months, respectively. One patient showed a
                      dramatic radiologic and clinical response after one week of
                      treatment. We were able to generate an ex vivo tumor cell
                      culture from CSF in one patient. Treatment of this cell
                      culture with dabrafenib resulted in reduced cell density and
                      inhibition of ERK phosphorylation in vitro. To date, this is
                      the first series on adult patients with BRAF-mutated
                      malignant glioma and leptomeningeal dissemination treated
                      with dabrafenib monotherapy. All patients showed a dramatic
                      response with one patient showing an ongoing response for
                      more than two years.},
      cin          = {INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-4-20090406},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29039591},
      UT           = {WOS:000417320500001},
      doi          = {10.3892/or.2017.6013},
      url          = {https://juser.fz-juelich.de/record/838853},
}